The Peter Attia Drive

Af
- MD
- Peter Attia

0 Anmeldelser: 0
Afsnit: 448
Gns. varighed: 1T 5M
Sprog: Engelsk
Format
Kategori: Personlig udvikling

Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.

Episodes

#400 ‒ AMA #87: Environmental pollution and longevity: air pollution, noise, light, EMFs, and practical strategies to mitigate health risksView the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the evidence behind environmental pollution and its impact on long-term health, separating well-supported risks from less substantiated claims while providing a practical framework for deciding which exposures deserve attention. He explains what environmental pollution encompasses, where it fits within the broader hierarchy of longevity interventions, and why studying its health effects is uniquely challenging. Peter examines the evidence linking air pollution to disease and shares actionable strategies for improving indoor and outdoor air quality. He also discusses how noise and light pollution can influence sleep, cardiovascular health, and overall well-being, offering practical ways to reduce their effects in daily life. Finally, Peter takes an evidence-based look at electromagnetic fields (EMFs) and 5G technology, evaluating the current science and whether concerns about these exposures are supported by the available data. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #87 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: • Defining environmental pollution and its role in longevity [1:45]; • Why the topic of environmental pollution is both polarizing and difficult to study [6:00]; • Where environmental exposures fit within the hierarchy of health priorities, and a framework for evaluating which environmental risks are worth addressing [13:15]; • Understanding air pollution: the major pollutants and why PM2.5 is a key marker of health risk [16:00]; • Indoor air pollution: why indoor air quality often matters most for reducing personal air pollution exposure [21:45]; • How air pollution is measured and how the Air Quality Index (AQI) translates pollution data into practical guidance [25:00]; • The health effects of air pollution: evidence linking exposure to respiratory and cardiovascular disease [27:00]; • How air pollution causes disease: biological mechanisms linking pollution to respiratory and cardiovascular health [29:15]; • Who is most susceptible to the health effects of air pollution? [31:45]; • Understanding air pollution thresholds and the differences between WHO and EPA air quality guidelines [34:15]; • Comparing acute air pollution events with chronic exposure and cumulative health risk [36:15]; • Best strategies for mitigating air pollution exposure [38:00]; • Noise pollution: effects on hearing, sleep, and cardiovascular health [44:30]; • Measuring noise exposure and understanding the thresholds for hearing loss and chronic health effects [48:00]; • Practical strategies to reduce noise exposure and protect your hearing [54:15]; • Light pollution: defining light pollution and the importance of timing for circadian health [58:15]; • The health effects of artificial light at night and the evidence behind blue light and blue light-blocking glasses [1:00:00]; • Practical strategies for optimizing light exposure to support circadian rhythms and sleep [1:04:00]; • Concerns about EMF and 5G exposure: understanding electromagnetic fields and the distinction between ionizing and non-ionizing radiation [1:06:30]; • Evaluating the evidence linking radiofrequency electromagnetic fields to cancer risk [1:10:15]; • Evaluating the evidence for electromagnetic hypersensitivity and EMF-related symptoms [1:14:00]; • Practical recommendations for managing everyday EMF and 5G exposure and avoiding unnecessary interventions [1:15:30]; • Prioritizing environmental exposures based on their impact on health and longevity [1:18:00]; • The highest-ROI strategies for reducing environmental pollution exposure and protecting long-term health [1:19:30]; and • More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
453|19M
#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer's disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer's disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care. We discuss: • Gayatri's training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer's care [3:45]; • How Alzheimer's disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15]; • The emerging role of neuroinflammation and viral infections in Alzheimer's disease [13:30]; • Gayatri's comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45]; • Why forgetting names is usually normal and when word-finding problems become concerning [29:00]; • Why women are at higher risk for Alzheimer's disease and how menopause influences cognition [33:45]; • The promise and limitations of blood-based biomarkers for diagnosing Alzheimer's disease [40:15]; • When preclinical Alzheimer's screening is appropriate and how to interpret positive biomarker results [45:00]; • Case study: early Alzheimer's prevention in a highly-functional woman in her 50s with two copies of APOE4 [47:15]; • Anti-amyloid therapies: balancing clinical benefit with ARIA risk using slow titration [51:45]; • The aducanumab controversy, why it was discontinued, and why Gayatri would still choose it [1:00:00]; • How anti-amyloid therapies cause ARIA, strategies for detecting and managing these complications, and how future therapies may improve safety and accessibility [1:03:30]; • Two patient examples of exceptional responses to anti-amyloid therapy [1:12:30]; • A multimodal approach to Alzheimer's treatment: combination therapy, MRI-guided TMS, GLP-1 receptor agonists, and more [1:15:00]; • Vascular dementia, Lewy body dementia, and the overlap with Alzheimer's disease [1:21:00]; • Lewy body dementia and Parkinson's disease: distinguishing two alpha-synuclein disorders [1:26:45]; • Risk factors for Lewy body dementia and what remains unknown [1:36:15]; • Treating menopause-related cognitive impairment: hormone therapy, brain rehabilitation, and balancing breast cancer risk [1:38:45]; • How biomarkers changed Gayatri's perspective on the potential for Alzheimer's patients to improve [1:47:15]; • The future of Alzheimer's care: AI, precision medicine, and personalized treatment [1:49:30]; and • More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
452|1T 56M
Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter dives deep into the topic of muscle mass and strength, examining their essential roles in both lifespan and healthspan. Drawing from over 30 hours of prior discussions with experts including Layne Norton, Andy Galpin, and Mike Israetel, this episode distills the most important insights into one comprehensive and up-to-date conversation. Peter explores why muscle matters for longevity, metabolic health, and injury prevention, and clarifies the differences between muscle mass and strength, including which is more vital for aging well. He breaks down practical strategies for building muscle safely and effectively, including progressive overload, training intensity, rep ranges, and the importance of explosive power. Peter also covers key nutrition strategies—like protein intake, timing, and creatine supplementation—and offers practical advice for everyone from beginners to seasoned lifters on building and maintaining muscle safely and sustainably. We discuss: • Peter's humorous experience talking nutrition with a second grader [3:00]; • Overview of topics, episode structure, and reasoning for focus on muscle mass and strength [6:30]; • Defining key terms: muscle mass, strength, hypertrophy, power, and more [8:45]; • The importance of muscular strength, muscle mass, and cardiorespiratory fitness for longevity [11:00]; • Grip strength as a simple yet powerful predictor of all-cause mortality [17:15]; • Is muscle strength causal or just a marker of health? [20:30]; • Why VO2 max, strength, and muscle mass are powerful health markers: a reflection of long-term consistent effort [23:00]; • How muscle mass and strength enhance healthspan by supporting metabolic health, inflammation control, recovery from illness, mobility, and fall prevention [24:15]; • How muscle mass and strength decline with age, and why it's essential to act early to slow decline and preserve function later in life [31:00]; • The foundational principles of building muscle strength and size through resistance training [36:00]; • How to apply "progressive overload" for long-term strength and muscle gains [40:00]; • The difference between concentric and eccentric muscle contractions and how each impacts strength, hypertrophy, and injury prevention [45:15]; • The differences between muscle fiber types, and how aging disproportionately affects fast-twitch fibers responsible for power [50:45]; • How to effectively train for power [52:30]; • Training intensity: the benefits and safety of using the "reps in reserve" method [53:30]; • How to balance compound and isolation exercises in a workout routine, and why compound lifts are foundational [56:15]; • Can bodyweight exercises build muscle as effectively as weight training? [58:15]; • How women can effectively build strength and muscle: key considerations [59:45]; • Effective methods for tracking progress in strength [1:01:45]; • Effective methods for tracking progress in muscle mass, and how to interpret results from a DEXA scan [1:05:00]; • How to balance workout frequency with recovery for optimal results [1:07:15]; • How to recognize signs of overtraining and when to consider taking rest days [1:10:45]; • Avoiding injury: how beginners or returning lifters can start resistance training safely [1:15:45]; • Protein: recommended intake, quality sources, timing of consumption, and more [1:18:00]; • How fasting and calorie restriction affect muscle mass and what can be done to minimize muscle loss [1:24:45]; • Key nutritional factors beyond protein that support muscle growth: hydration, creatine, and recovery [1:28:15]; • The impact of hormones, sleep, stress, and consistency on muscle building and recovery [1:29:15]; • How to structure an effective workout routine for a younger person who is new to resistance training [1:32:00]; • How to modify beginner resistance training programs for older individuals to prioritize safety and gradual progress [1:36:00]; • Should beginners start with machines or free weights when resistance training? [1:37:00]; • How experienced lifters should modify their training to support healthspan and performance in later life [1:38:30]; and • More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
451|1T 44M
#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight lossView the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: • The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45]; • Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45]; • How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15]; • Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30]; • Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15]; • The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00]; • Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45]; • Why lean mass measurements are an imperfect proxy for muscle health and function [21:45]; • The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00]; • Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00]; • Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00]; • Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45]; • Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00]; • Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00]; • Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45]; • Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15]; • Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00]; • The risks of using gray-market retatrutide before FDA approval [52:15]; • Key takeaways [54:30]; and • More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
450|9M
#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D.View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter View our full terms of use Renato Tomioka is a leading expert in reproductive medicine and gynecologic surgery whose unique skills allow him to diagnose and treat some of the most impactful yet frequently overlooked conditions affecting women's health. In this episode, Renato explores endometriosis and adenomyosis, explaining what these conditions are, why they often go undiagnosed for years despite affecting millions of women worldwide, and how advances in MRI and specialized ultrasound are transforming diagnosis beyond traditional surgical laparoscopy. He discusses the decision-making process behind hormonal therapy versus surgery, how treatment strategies change when fertility preservation is a priority, and where IVF fits into the care pathway for women with endometriosis, adenomyosis, or age-related fertility decline. Renato also examines the profound effects of female age on egg quality and quantity, including the accelerating rise in chromosomal abnormalities after age 35, highlights common mistakes in both surgical and fertility management, and shares promising developments on the horizon for treating these conditions and preserving fertility. Follow Dr. Tomioka's work: Instagram: @dr.renatotomioka; Website: Renato Tomioka, M.D., Ph.D. We discuss: • 0:00:00 - Intro • 0:00:11 - Endometriosis: definition, prevalence, infertility risk, and theories of disease development • 0:09:03 - The biology of endometriosis: estrogen dependence, progesterone resistance, and tumor-like growth mechanisms • 0:13:25 - Adenomyosis explained: how it differs from endometriosis, why it develops, and its impact on reproductive health • 0:18:52 - Recognizing endometriosis and adenomyosis: the "6 Ds" of endometriosis and key differences in clinical presentation • 0:22:09 - Uterine fibroids: classification, symptoms, and the importance of fibroid location for bleeding and fertility • 0:24:09 - Understanding endometriosis pain: lesion-driven pain, nerve involvement, central sensitization, and the importance of early treatment • 0:28:26 - Endometriosis in young women: rising prevalence, delayed diagnosis, and barriers to care • 0:33:11 - Modern diagnosis of endometriosis: specialized ultrasound, MRI, and the decline of diagnostic laparoscopy • 0:45:52 - Clinical case example #1: Managing endometriosis in a young woman seeking pain relief while preserving future fertility • 0:54:10 - Clinical case example #2: Comparing treatment strategies for symptom control versus fertility • 1:01:24 - Endometriosis and fertility: the roles of age, embryo quality, IVF, and surgery • 1:11:50 - Clinical case example #3: Managing adenomyosis after failed IVF transfers to improve implantation and pregnancy outcomes • 1:20:51 - The funding gap in endometriosis research: disease burden, economic impact, and growing awareness • 1:22:01 - Clinical case example #4: Surgical decision-making in endometriosis—balancing pain relief, fertility preservation, and common treatment pitfalls • 1:27:43 - Common misconceptions about fertility: maternal age, embryo aneuploidy, the inefficiency of human reproduction, and the limits of IVF • 1:34:23 - Elective egg freezing: timing, success rates, the fertility funnel, and the tradeoffs of fertility preservation • 1:45:49 - Emerging fertility technologies: mitochondrial replacement, ovarian tissue preservation, stem-cell-derived eggs, and current limitations • 1:55:10 - The future of endometriosis treatment: new guidelines, biologic therapies, and unanswered questions about IVF • 1:58:30 - Why earlier diagnosis matters: reducing years of suffering from endometriosis and adenomyosis Connect With Peter on Twitter, Instagram, Facebook and YouTube
449|1T 58M
#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategyView the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter explores the critical topic of breast cancer screening, examining why thousands of women continue to die from breast cancer each year despite the availability of effective screening tools. He explains the strengths and limitations of current screening strategies, reviews the recommendations from major medical organizations, and discusses why screening guidance can often seem confusing or contradictory. Peter outlines a practical framework for understanding breast cancer risk and personalizing screening decisions, including when to begin screening, how frequently to screen, and which imaging modalities may be most appropriate based on an individual's risk profile. Throughout the episode, he emphasizes that while population-based guidelines provide an important foundation, optimizing outcomes requires a more personalized approach aimed at helping women make informed screening decisions that can improve the chances of early detection and successful treatment. We discuss: • Why women still die from breast cancer: the benefits of screening, the problem of under-screening, and the need for risk-based screening strategies [1:45]; • Current screening recommendations, why they differ between organizations, and the importance of personalized screening decisions [6:30]; • A framework for personalizing screening [8:45]; • Assessing baseline breast cancer risk: genetics, family history, breast density, lifestyle factors, and the role of risk calculators in personalized screening [9:30]; • Balancing cancer detection and false positives: how breast cancer risk influences screening intensity and imaging choices [17:45]; • Mammography as the foundation of breast cancer screening: detecting ductal carcinoma in situ (DCIS) and the advantages of 3D versus 2D mammography [21:00]; • MRI for high-risk women: the benefits of supplemental screening, abbreviated MRI, and the emerging role of contrast-enhanced mammography [23:00]; • The role of ultrasound: supplemental cancer detection, diagnostic evaluation, and limitations compared with mammography and MRI [26:00]; • Choosing the right breast cancer screening strategy: imaging modality selection, screening hierarchies, and the importance of imaging center quality [28:00]; • How often should you screen for breast cancer? [30:15]; • At what age should you start screening? [37:30]; • Breast cancer in younger women: aggressive tumor biology, BRCA-related risk, breast density, and individualized decisions about when to begin screening [41:45]; • Inflammatory breast cancer, the limitations of screening mammography for symptomatic disease, and the importance of promptly evaluating new breast symptoms in both women and men [44:45]; • From risk assessment to personalized screening: a practical framework for reducing breast cancer mortality through earlier and more effective detection [46:30]; and • More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
448|50M
#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Tom Dayspring is a world-renowned lipidologist and one of the most thoughtful teachers in the field of lipid metabolism. In this episode, Tom returns to The Drive for a deep dive into the relationship between lipids and brain health, beginning with the fundamentals of cholesterol transport before exploring why the brain's cholesterol system operates almost entirely independently from the rest of the body. Tom examines the roles of apoB, apoA-I, and especially apoE in cholesterol homeostasis, discusses how APOE genotype influences Alzheimer's disease risk, and unpacks the complex links between cholesterol metabolism, amyloid, and tau pathology. He also reviews what is currently known—and still uncertain—about the effects of statins, ezetimibe, omega-3 fatty acids, and emerging CETP inhibitors on brain health and neurodegenerative disease risk. Although highly technical, this conversation provides an essential framework for understanding the nuanced relationship between lipid-lowering therapies, cardiovascular disease prevention, and neurodegenerative diseases in an area often clouded by misinformation. We discuss: • The fundamentals of cholesterol transport in the body, and how peripheral cholesterol metabolism differs from cholesterol handling in the brain [2:45]; • How cholesterol is transported through plasma and stored within cells, and why lowering LDL cholesterol does not deplete the body or brain of cholesterol [11:45]; • How apoB particles drive atherosclerosis, why lowering lipids matters, and the factors that influence individual cardiovascular risk [20:00]; • How the brain produces and transports its own cholesterol using apoE lipoproteins independently of circulating cholesterol and apoB-containing lipoproteins [29:00]; • How apoB structure influences LDL receptor binding and LDL clearance [39:00]; • How neurons acquire cholesterol from apoE-containing lipoproteins and why desmosterol serves as a unique marker of cholesterol synthesis in the brain [41:45]; • The difference between the APOE gene and the apoE protein, the major APOE genotypes found in humans, and how APOE4 influences Alzheimer's disease risk [48:45]; • HDL function beyond cholesterol: immune function, protein cargo, and communication with the brain [53:30]; • How APOE4-associated defects in brain cholesterol transport may promote Alzheimer's disease: amyloid production, neuronal cholesterol homeostasis, and cholesterol clearance [58:00]; • Statins and brain health: reviewing the evidence of the potential impact of statins on cognition and Alzheimer's disease risk [1:09:00]; • Desmosterol and 24S-hydroxycholesterol as biomarkers of brain cholesterol metabolism and statin effects [1:17:15]; • Possible cognitive benefits of ezetimibe beyond lowering apoB [1:19:30]; • EPA, DHA, and the evidence for omega-3 fatty acids in brain health [1:23:15]; • Obicetrapib: an emerging CETP inhibitor with potential implications for both cardiovascular and brain health [1:31:00]; and • More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
447|1T 40M
#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplementsView the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter dives into the pharmacology of sleep, exploring where sleep medications fit within the broader framework of achieving healthy, restorative sleep. He explains why sleep is a biological imperative, why behavioral and environmental interventions must remain the foundation of good sleep, and how medications can serve as useful tools when carefully matched to a person's specific sleep problem. Peter examines the major classes of prescription sleep medications, including how they work, their effects on sleep architecture, their duration of action, side effects, and risks of tolerance and dependence. He also discusses the dangers of using sleep drugs without a clear understanding of the underlying problem being treated, the role of medications as short-term bridges during periods of acute stress, pain, or anxiety, and the promise that newer drugs like DORAs may hold for Alzheimer's prevention in high-risk individuals. Finally, Peter reviews the evidence for select off-label medications and supplements commonly used for sleep. We discuss: • The biological foundations of sleep, the major drivers of sleep dysfunction, and the role sleep medications can play when appropriately matched to specific sleep problems [1:00]; • Sleep hygiene, circadian alignment, and the medical causes of insomnia: building the foundation for effective sleep treatment [7:15]; • Understanding insomnia: hyperarousal, CBT-I, paradoxical insomnia, and why different sleep problems require different treatments [12:45]; • The difference between sedation and physiologic sleep: sleep architecture, restorative sleep stages, and matching medications to specific sleep problems [17:00]; • Benzodiazepines for insomnia: mechanisms, effects on sleep architecture, and the risks of long-term use [18:45]; • Z-drugs for insomnia: how Ambien, Sonata, and Lunesta work, and the ongoing risks of sleep medications targeting GABA systems [23:00]; • Dual orexin receptor antagonists (DORAs) and the future of sleep medicine: orexin signaling, sleep architecture, and the emerging connection between sleep and Alzheimer's disease [27:15]; • Melatonin for circadian timing: how timing signals differ from sedatives in the treatment of sleep disorders [36:30]; • Trazodone for insomnia: preserving deep sleep while minimizing the risks of traditional sedative-hypnotics [42:00]; • First-generation antihistamines for sleep: short-term sedation, anticholinergic risks, and concerns about long-term cognitive health [44:00]; • Sleep supplements and the evidence behind them: glycine, magnesium, ashwagandha, phosphatidylserine, and more [45:45]; • Takeaways: supplement quality, individualized sleep treatment, and the importance of matching interventions to the biology of insomnia [52:00]; and • More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
446|54M
#393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they're working for youView the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores how to think critically about medications and supplements by focusing not on whether an intervention is inherently "good" or "bad," but on whether it makes sense for a specific person with a specific problem. He explains why clearly defining the problem matters more than choosing the intervention itself, how the intended purpose of a medication or supplement should influence the standard of evidence required, and why mechanistic reasoning alone is rarely enough to justify taking something. Peter also examines how baseline risk shapes the true benefit of an intervention, why relative risk statistics can be misleading without proper context, and how to weigh not only side effects, but also cost, inconvenience, and opportunity cost when deciding whether something is worth taking. Additionally, he discusses practical ways to evaluate whether a supplement is actually having a meaningful effect, how to think about discontinuing therapies, why supplements deserve far more skepticism than they often receive, and the small group of over-the-counter supplements he believes may offer a reasonable risk-reward trade-off. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #85 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: • How to properly define health problems before considering medications or supplements [1:45]; • How the intended purpose of an intervention should determine evidence standards and risk tolerance [5:00]; • Understanding the hierarchy of evidence for medications and supplements and avoiding the mistake of treating weak evidence as clinical proof [9:00]; • Why mechanistic explanations can be misleading when evaluating longevity interventions [13:15]; • How baseline risk—and the distinction between relative and absolute risk reduction—changes the real-world benefit of medications and supplements [18:15]; • Thinking beyond side effects: the many forms of downside associated with medications and supplements [22:45]; • Why medications and supplements require different standards of trust and evidence [26:00]; • How to structure meaningful self-experiments with medications and supplements to determine if it's they're working [30:30]; • How to monitor the effects of medications and supplements without fooling yourself [32:30]; • How to periodically reevaluate and potentially discontinue medications and supplements [35:15]; • The biggest risks and failure modes of over-the-counter supplements: efficacy, poor quality control, contamination, interactions, toxicity, and marketing-driven overuse [38:30]; • Why the US supplement regulatory system creates unreliable products [41:45]; • A practical framework for evaluating medications and supplements [46:30]; • Over-the-counter supplements with the best balance of evidence and low downside risk [48:00]; and • More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
445|13M
#392 - Genetic testing: when it's valuable, how to choose the right test, and what to do with the resultsView the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter explores the complex and often misunderstood world of genetic testing, building a practical framework for understanding what these tests can and cannot actually tell us about health and disease. He explains why some genetic findings can be genuinely life-changing while many others offer information that is far more probabilistic than deterministic, and why directly measuring the phenotype is often more valuable than inferring risk from DNA alone. Peter examines where genetics can provide meaningful insight across the major disease categories and where its predictive power is far more limited than many people assume. He also discusses how to think critically about different types of genetic tests, how to interpret results in the proper context, and how to avoid the common trap of accumulating more genetic information without gaining greater clarity or actionable insight. We discuss: • Genetic testing: understanding what it can reveal, where it falls short, and how to think about its clinical value [1:45]; • The Human Genome Project: why decoding DNA did not immediately unlock the mysteries of disease [4:15]; • The limitations of genetic testing: probabilistic risk, interpretive uncertainty, and the importance of phenotype [9:30]; • Questions to ask when considering genetic testing [15:45]; • Genetic testing in cardiovascular and metabolic disease: when genotype adds value beyond phenotype [17:00]; • Genetic testing for inherited cardiac conditions: identifying hidden risk beyond routine screening [21:45]; • Genetic testing for cancer risk: inherited syndromes, clinical utility, and the limits of consumer testing [24:00]; • Genetic testing for neurodegenerative disease: risk prediction, planning, and the challenge of limited actionability [28:45]; • Functional medicine genetic testing: the gap between biological plausibility and clinical evidence, and the supplement protocols that aren't supported by evidence [32:45]; • Pharmacogenetics: using genetic testing to guide medication selection and safety [38:45]; • A framework for evaluating genetic tests according to effect size and clinical actionability [41:45]; • The major types of genetic tests, and how each should be matched to the clinical question being asked [43:30]; • Interpreting genetic test results: choosing the right testing laboratory and understanding what the findings actually mean [49:45]; • Framework summary: why genetic testing is most valuable when it is guided by a clear question, matched with the appropriate test, and capable of meaningfully influencing decisions [56:45]; and • More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
444|1T 2M

The Peter Attia Drive

Episodes

Lyt når som helst, hvor som helst

Andre har også lyttet til ...